Shikari® (Q-NAT) Natalizumab ELISA
NAT-FD-TYS
Enzyme immunoassay for the quantitative determination of Natalizumab (Tysabri®) in human serum and plasma.
This kit has been especially developed for the quantitative determination of natalizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.
Natalizumab Drug Bank Accession Number is DB00108.
Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 100 |
| Total Time (min) | 70 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 10 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Safety Data Sheet (SDS) | Download | |
| Instructions For Use | Download | |
| Validation Report | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Kadhim, Abbas Ahmed, Mohammed Yawuz Jamal, and Ali Kadhim Karim. "Natalizumab Immunogenicity in Multiple Sclerosis: Evaluating Antibody Development and Clinical Outcomes in an Iraqi Cohort." Al-Rafidain Journal of Medical Sciences (ISSN 2789-3219) 9.2 (20 | Download |